Trial Profile
Impact of belimumab given in addition to standard of care therapy on 13-valent conjugated pneumococcal vaccine (PCV13) response in patient with systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 24 May 2018 New trial record